Pacira BioSciences, Inc. (PCRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$26.35-0.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · PCRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Entry Into a Material Definitive Agreement. On June 28, 2026, Pacira BioSciences, Inc. (the “Company”) and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary (the “Subsidiary”), entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with Zimmer, Inc. (the “Purchaser”), a subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”). Pursuant to the Purchase Agreement, the Company has agreed to divest to the Purchaser (i) all of the issued and outstanding capital…
The filing details the approval of an amended stock purchase plan and committee reassignments, which are routine administrative matters.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Director — Dr. Samit Hirawat: The filing discloses the appointment of a new independent director to an expanded board, which is a routine governance action rather than a departure of a senior executive.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Costs Associated with Exit or Disposal Activities. On July 9, 2025, Pacira BioSciences, Inc. (the “Company”) instituted a reduction in force at the Company’s Science Center Campus in San Diego, California as a result of improving manufacturing efficiencies for EXPAREL ® (bupivacaine liposome injectable suspension). The Company’s enhanced efficiencies are the result of its multi-year investment in two large-scale 200+ liter batch manufacturing suites located in San Diego and Swindon, United Ki…
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements Any statements in this Current Report on Form 8-K abo…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Termination of a Material Definitive Agreement. On July 3, 2025, the Company used a portion of the $300.0 million of revolving loans to repay the indebtedness outstanding under the Existing Credit Agreement and terminated the Existing Credit Agreement. The Company did not incur any prepayment penalties or fees in connection with the termination of the Existing Credit Agreement. A description of the Existing Credit Agreement is included in the Company’s Current Reports on Form 8-K, filed with…
Entry into a Material Definitive Agreement. On July 3, 2025, Pacira BioSciences, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank, and certain lenders, to, among other things, refinance the indebtedness outstanding under the Company’s credit agreement, dated as of March 31, 2023, as amended to date, relating to the Company’s term loan A facility (the “Existin…
The filing discloses the approval of an amended stock incentive plan, which is a compensatory arrangement rather than a change in management or board composition.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Other Events. On April 17, 2025, Pacira BioSciences, Inc. (the “Company”) announced that its Board of Directors has approved a new share repurchase program, effective immediately, which authorizes the Company to purchase up to an aggregate of $300.0 million of the Company’s outstanding common stock, which replaces the Company’s previous share repurchase program announced on May 7, 2024. Repurchases under this program may be made at management’s discretion on the open market or through private…
Entry into a Material Definitive Agreement. On April 7, 2025, Pacira BioSciences, Inc. (the “Company”) and its wholly-owned subsidiary Pacira Pharmaceuticals, Inc. entered into a Settlement Agreement (the “Settlement Agreement”) with Fresenius Kabi USA, LLC (“Fresenius Kabi”), eVenus Pharmaceutical Laboratories Inc., (“eVenus”), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (f/k/a Jiangsu Hengrui Medicine Co., Ltd, “Jiangsu” and, together with Fresenius Kabi USA, LLC and eVenus Pharmaceutical…
of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Director — Paul J. Hastings: The Chair of the Board and another director resigned simultaneously, reducing the board size, but the filing notes no disagreement with the company and a successor Chair was immediately appointed.
Chief Commercial Officer — Brendan Teehan: The filing discloses the appointment of a new Chief Commercial Officer and a concurrent internal role change for the former COO, which is a standard executive succession event rather than a departure.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
The filing discloses amendments to executive employment agreements regarding severance and change-of-control provisions, not an actual departure, appointment, or election of officers.
CFO — Shawn M. Cross: The filing announces the appointment of an external candidate as CFO to succeed an interim officer, which is a standard executive succession event rather than a sudden departure or loss of a sitting executive.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.